Airway Basal Stem Cells

Phase 1Biologic

RRegend Therapeutics

Airway Basal Stem Cells is one of 15 biologic programs targeting Bronchiolitis Obliterans. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bronchiolitis ObliteransRecruiting

Bronchiolitis ObliteransPhase 1

Recruiting

Competition

Competitive Landscape

15 competitors in Bronchiolitis Obliterans

#DrugCompanyPhaseTrials

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

5 2

Biaxin

Neoral

Singulair

2 5

Esbriet

LLegacy Health System

Foradil

Pulmicort

Velcade

SShilpa Grover, MD, MPH

Ofev

2 10

Jakafi

Incyte

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Bronchiolitis Obliterans

NCT07239895

Clinical

Trials by Indication[1]

Bronchiolitis Obliterans1 trial

Treatment of Pediatric Bronchiolitis Obliterans by Airway Basal Stem Cells

Recruiting·RRegend Therapeutics·Phase 1·NCT07239895·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Airway Basal Stem Cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Airway Basal Stem Cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Airway Basal Stem Cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regend Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: RRegend Therapeutics

Airway Basal Stem Cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Bronchiolitis Obliterans1 trial

References

Drug Info

Quick Facts

Related News